• SJ572946 Activates BAK to Initiate Apoptosis

  2026-10-03

  The 2022 iScience study identifies SJ572946 as a fragment-derived small molecule that binds the BAK activation groove and promotes mitochondrial apoptosis. Its evidence supports SJ572946 as a preclinical tool for studying BAK-selective activation and combination strategies, while leaving questions about pharmacology, tumor selectivity, and in vivo applicability unresolved.

• DAPI (hydrochloride) for Cell Cycle Analysis

  2026-10-02

  DAPI (hydrochloride) provides a practical DNA readout for chromosome staining, histochemistry, microscopy, and selected flow-cytometry workflows. This guide connects its minor-groove binding chemistry with fixed-cell, live-cell, and multiparameter assay design while emphasizing controls, optimization, and interpretation limits.

• IGU Prodrug Disrupts STAT1–C3–TNFα Crosstalk

  2026-10-01

  The reference study identifies TYK2 JH2-dependent control of STAT1 as a mechanism by which iguratimod suppresses rheumatoid arthritis fibroblast-like synoviocyte invasiveness. It further shows that an iguratimod prodrug, AD811, preserves activity in collagen-induced arthritis while interrupting a complement C3–TNFα feedback loop between synovial fibroblasts and macrophages.

• Eldecalcitol and Endothelial Ferroptosis in T2DOP

  2026-10-01

  A 2025 study identifies endothelial ferroptosis as a mechanistic contributor to type 2 diabetic osteoporosis and connects the protective activity of eldecalcitol to the SOCE/O-GlcNAcylation axis. Its combined cell and mouse experiments link calcium signaling, lipid oxidation, angiogenesis, and osteogenesis, providing a framework for evaluating vascular mechanisms in diabetic bone disease.

• Tiamulin (Thiamutilin) for PK/PD Research

  2026-09-30

  Tiamulin combines targeted pleuromutilin antibacterial activity with an emerging anti-inflammatory research profile, making it useful for both pathogen-focused and pathway-focused workflows. This guide translates chicken infection-model PK/PD findings into practical assay design, dosing interpretation, and troubleshooting steps.

• Direct Mouse Genotyping Kit Plus for Disease Models

  2026-09-30

  The Direct Mouse Genotyping Kit Plus supports rapid, purification-free PCR workflows for complex mouse genotyping assays. This article connects genotype quality control with the EP4–CD36 atherosclerosis model, showing how assay design can strengthen mechanistic interpretation.

• STMN2 Depletion, Translation Deficits, and Stress Granules

  2026-09-29

  The reference study shows that stress can deplete neuronal STMN2 through proteasomal degradation, phosphorylation, and stress-granule-associated translation repression, independently of TDP-43 splicing dysfunction. Its combination of neuronal models, single-molecule translation and RNA-localization analyses, pharmacological perturbations, and longitudinal survival measurements provides a broader framework for understanding STMN2 vulnerability in ALS.

• Azilsartan as a Causal Probe of Glial RAS

  2026-09-29

  Azilsartan (TAK-536) offers translational researchers a selective way to test whether AT1 signaling connects microglia-derived inflammatory cues with reactive astrocyte phenotypes. This thought-leadership article interprets recent RAS–SIRT3 findings, proposes a disciplined assay framework, and defines what remains to be demonstrated beyond cell-based models.

• Ruxolitinib Phosphate: JAK Signaling to Mitochondria

  2026-09-28

  A translational perspective on how Ruxolitinib phosphate and INCB018424 connect JAK1/2 inhibition with STAT3-dependent mitochondrial dynamics, apoptosis, and pyroptosis in anaplastic thyroid carcinoma research.

• TTP–WTAP–m⁶A Signaling Limits Schistosomal Fibrosis

  2026-09-28

  A 2026 study identifies tristetraprolin (TTP) as a protective regulator of Schistosoma japonicum–induced liver fibrosis, linking TTP to WTAP transcription and m⁶A-dependent destabilization of TGF-β1 mRNA. The results extend TTP biology beyond its canonical role in mRNA decay and suggest a pathway for investigation, while leaving important questions about cell specificity and therapeutic translation.

• 3-Deazaadenosine for Methylation Pathway Research

  2026-09-27

  Use 3-Deazaadenosine as a broad pharmacological probe to test whether methylation capacity contributes to inflammatory or viral phenotypes—not as a selective METTL14 inhibitor. A staged dose-and-time workflow helps separate pathway effects from cytotoxicity and connects the ulcerative-colitis findings of Wu et al. to experimentally testable hypotheses.

• Optimizing Functional Platelet Production from hiPSCs

  2026-09-26

  Yue and colleagues optimized an embryoid-body-based hiPSC differentiation workflow by adjusting cell input and culture conditions and incorporating small molecules at distinct stages. The reported protocol produced thrombin-responsive platelets in 19 days, with higher output and lower reported costs, while its results should not be attributed to SU6656, which was not part of the highlighted maturation combination.

• Tiamulin (Thiamutilin): PK/PD Workflows

  2026-09-25

  Use Tiamulin to connect ribosomal target engagement with practical antibacterial and inflammation-assay questions. A chicken infection study shows why exposure relative to MIC—not dose alone—is the more informative guide for interpreting efficacy.

• Amikacin Sulfate: Workflows for Infection Models

  2026-09-25

  Build practical Amikacin Sulfate workflows for bacterial susceptibility, CFU killing, and intracellular uptake studies. The guide pairs reported activity data with assay controls and troubleshooting, while flagging a MIC-unit discrepancy that should be resolved before experiments are interpreted.

• Covalent HPV16 E6 Inhibition Restores p53

  2026-09-24

  The study reports covalent inhibitors that irreversibly inactivate HPV-16 E6, restore p53 signaling, and suppress growth of HPV-driven cervical and oropharyngeal tumors in mouse models. Genetic resistance controls support an on-target mechanism, while the reported senescence response may be studied as a complementary cellular phenotype—not as a substitute for measuring E6 inhibition or p53 restoration.

8040 records 1/536 page Next 12345 下5页 Last page